Antivascular therapy after recurrence of glioblastoma:anlotinib vs bevacizumab
10.3781/j.issn.1000-7431.2024.2402-0089
- VernacularTitle:胶质母细胞瘤复发后的抗血管治疗:安罗替尼与贝伐珠单抗的比较
- Author:
Jin ZHOU
1
;
Haoyun LIU
;
Haoyu ZHANG
;
Xinyue YANG
;
Ruizhi WANG
;
Renhua HUANG
Author Information
1. 上海交通大学医学院附属仁济医院放疗科,上海 200127
- Publication Type:Journal Article
- Keywords:
Glioblastoma;
Recurrence;
Anlotinib;
Bevacizumab
- From:
Tumor
2024;44(9):971-978
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore whether anlotinib or bevacizumab has better efficacy in patients with recurrent glioblastoma.Methods:The clinical characteristics and treatment data of patients with recurrent glioblastoma admitted to Ren Ji Hospital,Shanghai Jiao Tong University School of Medicine,were collected retrospectively.All patients received maximal resection of the tumor combined with postoperative adjuvant radiotherapy and chemotherapy,and the recurrence was detected by head contrast-enhanced MRI.According to the choice of anti-vascular therapy,the patients were divided into anlotinib group and bevacizumab group.Survival curves were drawn to compare the overall survival time of the two groups of patients,and subgroup analysis was performed according to the basic information of the patients and whether they received temozolomide chemotherapy or radiotherapy after recurrence.Results:A total of 37 patients were enrolled in the study,19 in the anlotinib group and 18 in the bevacizumab group.The median overall survival time was 16.3 months,with 19.6 months in the anlotinib group and 12.8 months in the bevacizumab group.However,survival analysis showed that there was no significant difference in survival time between the anlotinib group and the bevacizumab group(P=0.88).Further subgroup analysis showed that there was no significant difference in survival time between the two groups in all subgroups.Conclusion:This study provided an initial indication of the efficacy of anlotinib in patients with recurrent glioblastoma and suggested that oral anlotinib may be a viable option for patients who were unable to tolerate bevacizumab or who had.
